 COPENHAGEN, Denmark LAUSANNE, Switzerland--BUSINESS WIRE--Genmab AS Nasdaq: GMAB and ADC Therapeutics SA NYSE: ADCT today announced that they have executed an amended agreement for ADC Therapeutics to continue the development and commercialization of camidanlumab tesirine Cami. The parties first entered into a collaboration and license agreement in June 2013 for the development of Cami, an antibody drug conjugate ADC which combines Genmabs HuMax-TAC antibody targeting CD25 with A 